PhoenixBio, based in Higashihiroshima, Hiroshima Prefecture, reported strong domestic sales of mice implanted with human livers in its interim results. However, it lost orders for contract testing from a major U.S. pharmaceutical customer, resulting in a fourth consecutive year of revenue decline and a return to a net loss after 2 years.
Sales of mice implanted with human livers were strong in the domestic market.
The company lost orders for contract testing from a major U.S. pharmaceutical customer, resulting in a fourth consecutive year of revenue decline.
Net income was in the red for the first time in 2 years.